Real-world comparative benefits and risks of infliximab (IFX) and adalimumab (ADA) in patients with ulcerative colitis (UC) is unclear
International audienceBackground - Few data exist to help select a second biologic agent in patients...
Background and Aims There is an unmet need to better understand the effectiveness of different biolo...
Aim: To assess the efficacy of infliximab in ulcerative colitis (UC) patients who had failed therapy...
Real-world comparative benefits and risks of infliximab (IFX) and adalimumab (ADA) in patients with ...
PURPOSE: Data on the comparative effectiveness of infliximab (IFX) or adalimumab (ADA) in patien...
Background/aims: The tumor necrosis factor-α inhibitors infliximab and adalimumab are standard treat...
INTRODUCTION: There are no real-life studies comparing the efficacy and safety of the different anti...
Background: Adalimumab (ADA) and vedolizumab (VDZ) have shown efficacy in moderate to severe ulcerat...
Background and Aim: Adalimumab [ADA] was approved for the treatment of ulcerative colitis [UC] refr...
Background: Adalimumab (ADA) and vedolizumab (VDZ) have shown efficacy in moderate to severe ulcerat...
BACKGROUND: Head-to-head comparison studies evaluating the effectiveness and tolerability of anti-TN...
Introduction: The aim of the study was to compare adalimumab or golimumab with infliximab in patient...
BACKGROUND: Adalimumab (ADA) and vedolizumab (VDZ) have shown efficacy in moderate to severe ulcera...
Introduction: Adalimumab (ADA) and golimumab (GOL) are effective in the induction and maintenance tr...
Background and aims: The effectiveness of adalimumab in the treatment of ulcerative colitis is under...
International audienceBackground - Few data exist to help select a second biologic agent in patients...
Background and Aims There is an unmet need to better understand the effectiveness of different biolo...
Aim: To assess the efficacy of infliximab in ulcerative colitis (UC) patients who had failed therapy...
Real-world comparative benefits and risks of infliximab (IFX) and adalimumab (ADA) in patients with ...
PURPOSE: Data on the comparative effectiveness of infliximab (IFX) or adalimumab (ADA) in patien...
Background/aims: The tumor necrosis factor-α inhibitors infliximab and adalimumab are standard treat...
INTRODUCTION: There are no real-life studies comparing the efficacy and safety of the different anti...
Background: Adalimumab (ADA) and vedolizumab (VDZ) have shown efficacy in moderate to severe ulcerat...
Background and Aim: Adalimumab [ADA] was approved for the treatment of ulcerative colitis [UC] refr...
Background: Adalimumab (ADA) and vedolizumab (VDZ) have shown efficacy in moderate to severe ulcerat...
BACKGROUND: Head-to-head comparison studies evaluating the effectiveness and tolerability of anti-TN...
Introduction: The aim of the study was to compare adalimumab or golimumab with infliximab in patient...
BACKGROUND: Adalimumab (ADA) and vedolizumab (VDZ) have shown efficacy in moderate to severe ulcera...
Introduction: Adalimumab (ADA) and golimumab (GOL) are effective in the induction and maintenance tr...
Background and aims: The effectiveness of adalimumab in the treatment of ulcerative colitis is under...
International audienceBackground - Few data exist to help select a second biologic agent in patients...
Background and Aims There is an unmet need to better understand the effectiveness of different biolo...
Aim: To assess the efficacy of infliximab in ulcerative colitis (UC) patients who had failed therapy...
DOI
Add to ORKG